摘要
目的：观察阿托伐他汀对糖尿病患者肾脏的保护作用.方法：66例DN患者随机分为常规治疗组（A组）和阿托伐他汀组（B组）,B组在A组治疗的基础上加用阿托伐他汀30 mg/d,疗程共12周.比较两组患者治疗前后FBG、BUN、Scr、尿微量白蛋白（UAER）及血脂水平;并以同期在本院进行健康体检的30例作为对照组（C组）,检测三组外周血单个核细胞NF-κB活性.结果：治疗后,B组患者BUN、UAER 血脂水平较治疗前明显改善;B组患者外周血单个核细胞NF-κB活性较A组降低,两组之间的差异具有显著性意义（p＜0.05）.与C组比较,A、B两组外周血单个核细胞NF-κB活性明显升高,差异有统计学意义（p＜0.05）.结论：NF-κB与DN的发生有一定的关系,阿托伐他汀能降低DN患者血脂和外周血单个核细胞NF-κB活性,具有肾脏保护作用.
Objective：To observe the renoprotection effective of atorvastatin ot. diabetic nephropathy （DN）, Methods： 66 patiehts of DN were randomly divided into A group and B group. B group, on the basis of the control group, were treated by atorvastatin 30 mg once a day, with a treatment course of 12 weeks for both groups. Levels of FBG, BUN, Scr, UAER and blood lipid （TC, TG, LDL--C and HDL--C） were tested. 30 cases of healthy person over the period were as control group （C group）, and the NF-κB activity of peripheral blood mononuclear cells （PBMCs） were detected in three groups. Results： After treatment with atorvastatin, the level of BUN, UAER and blood lipid was obviously improved. Compared with C group, the NF-κB activity of PBMCs in all DN cases was significantly higher, and the NF-κB activity of PBMCs was decreased obviously in B group than in A group. Conclusion： NF-κB was associated with the incidence of DN. Atorvastatin can reduce the NF-κB activity of peripheral blood mononuclear cells in patients with DN and low the level of blood lipid, displayed a reno--protection effect.
